CSII

ANALYST NOTE: CSII (Cardiovascular Systems, Inc.) Date: 2026-06-13 Current Price: $20.00

1. Structural Readiness

Conservative Entry: — (Not yet triggered; requires a close above the breakout level) Breakout Level: — (Not yet defined; requires the formation of the specific resistance level during the current consolidation) Current Price: $20.00 Extension: — (No extension data available as the breakout has not fired) ATR Current: 0.2% (Sub-threshold volatility)

Analysis:

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED There is NO named secular thesis or macro theme attached to this name as of 2026-06-13. This is not a "buy the thesis" situation based on a broad industry tailwind (e.g., "The Great Aging" or "Global PAD Surge") that is currently driving the narrative. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals available in the evidence base. We are not inventing a macro narrative; we are evaluating a tactical opportunity based on structural readiness and company-specific execution.

3. Business Fundamentals

Company Overview: Cardiovascular Systems, Inc. (CSII) is a medical technology firm dedicated to the creation and commercialization of advanced therapeutic solutions for peripheral and coronary artery diseases. The company serves markets both within the United States and internationally.

Business Model & Industry:

• Industry: Medical Technology / Cardiovascular Devices.
• Model: Development, manufacturing, and distribution of catheter-based systems and procedural accessories.
• Core Products:
• Peripheral: Systems for treating peripheral artery disease (PAD), including severely calcified deposits above and below the knee.
• Coronary: The Diamondback 360 Coronary Orbital Atherectomy System (OAS).
• Accessories: Guidewires, catheters, balloons, and embolic protection systems.

Evidence & Performance (As of 2026-06-13): The most recent substantive financial guidance and operational data available in the evidence base dates to 2022-11-05. While this is historical relative to the 2026 event date, it represents the last recorded "source" of specific management expectations and financial targets.

• Guidance: Management reiterated fiscal '23 guidance assuming a gradual improvement in U.S. hospital procedure volumes. They projected revenue of $255 million to $265 million, representing 8% to 12% annual growth.
• Product Performance:
• Peripheral ISDs: Management stated they were on track to achieve $200 million of incremental revenue from peripheral ISDs by fiscal year end.
• Scoreflex Balloon: Launched in Q1, generating over $1.7 million in sales, driving a 70% increase in coronary ISD revenue to $4.5 million.
• Max Crown: Launched in October for peripheral OAS to treat lesions above the knee.
• Pipeline Status (as of 2022):
• Coronary Microcatheters: 510(k) submissions filed in Q3.
• ECLIPSE Clinical Trial: Over 1,900 patients enrolled; anticipated completion later in fiscal year with data readout at TCT in calendar '24.
• FDA Presubmissions: Completed for coronary and peripheral; trials intended to initiate in fiscal '24 pending feedback.
• Collaborations: A partnership with Chansu Vascular Technologies for the development of everolimus drug-coated balloons for peripheral and coronary applications.

*Note: No financial data, earnings transcripts, or operational updates are available in the evidence base for the period between late 2022 and the event date of 2026-06-13. The business description relies on the 2022 profile and the 2022 guidance.*

4. Archetype and Conviction

Archetype: Growth Leader This classification is derived from the company's historical focus on high-growth product launches (Scoreflex, Max Crown) and the management's explicit guidance for 8-12% annual revenue growth. The archetype fits the "Growth Leader" profile because the company is positioned to expand its market share through new product introductions and international expansion, rather than relying on deep value recovery or defensive characteristics.

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: Low/Missing (The most recent specific financial data is from 2022. There is a 4-year gap in the evidence base between the last recorded guidance and the 2026 event date. We cannot verify if the 2022 guidance was met or if the pipeline milestones were achieved).
• Structural Quality: Moderate (The setup is "Forming," which is a positive structural signal, but the sub-threshold ATR (0.2%) indicates a lack of volatility and potential stagnation).
• Setup Readiness: Partial (Price is holding above support, but the breakout has not fired. The setup is not yet actionable).
• Rerating Potential: Unknown (Cannot be assessed without current financials or a confirmed breakout).

Valuation Context: No valuation metrics (P/E, P/S, EV/EBITDA) are available in the evidence base for 2026. The current price of $20.00 cannot be contextualized against earnings or revenue multiples without the missing financial data.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: Evidence (if available) that the company missed the 2022 guidance significantly or failed to launch the ECLIPSE trial readout or the 510(k) approvals as scheduled.
• Structural: A prolonged period of sub-threshold volatility (ATR < 2.5%) without a breakout, leading to a "dead cat" or stagnation scenario.

What Would Strengthen the Case:

• Fundamental: Confirmation that the 2022 guidance was met and that the new product lines (Scoreflex, Max Crown) have scaled beyond the initial $1.7M and $200M targets.

Honest Gaps in the Evidence Base:

• Critical Missing Data: There is no evidence for the period from late 2022 to June 2026. We do not know the actual 2023, 2024, 2025, or 2026 financial results.
• Missing Guidance: No current management guidance exists in the evidence base. We cannot know if management is currently raising or lowering expectations.
• Missing Clinical Data: We do not know the outcome of the ECLIPSE trial or the FDA feedback on the coronary/peripheral presubmissions mentioned in 2022.
• Missing Valuation: No current P/E or revenue multiples are available to assess if $20.00 is cheap or expensive.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: Forming coil structure with price holding above support; Historical growth guidance of 8-12% from 2022; Strong product launch performance (Scoreflex) in 2022. Key risks: Four-year gap in financial evidence (2022-2026); Sub-threshold ATR indicating lack of momentum; No current management guidance or valuation context; Potential failure of 2022 clinical trials to materialize. Sizing hint: Minimal position size due to missing evidence and low volatility; treat as a watchlist item until breakout confirmation. Expected path: Management expectations recorded in 2022 regarding volume recovery and product expansion would need to be validated by current financials; price likely to remain range-bound until volatility increases and a breakout occurs. Expected horizon: Indefinite; dependent on the resolution of the forming coil and the availability of updated financial data.